- Home
- IONS vs FCN Comparison
IONS vs FCN Comparison
Compare IONS & FCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- FCN
- Stock Information
- Founded
- IONS 1989
- FCN 1982
- Country
- IONS United States
- FCN United States
- Employees
- IONS N/A
- FCN N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- FCN Professional Services
- Sector
- IONS Health Care
- FCN Consumer Discretionary
- Exchange
- IONS Nasdaq
- FCN Nasdaq
- Market Cap
- IONS 6.0B
- FCN 7.0B
- IPO Year
- IONS 1991
- FCN 1996
- Fundamental
- Price
- IONS $32.32
- FCN $164.95
- Analyst Decision
- IONS Buy
- FCN Strong Buy
- Analyst Count
- IONS 19
- FCN 1
- Target Price
- IONS $61.24
- FCN $275.00
- AVG Volume (30 Days)
- IONS 1.7M
- FCN 226.4K
- Earning Date
- IONS 02-19-2025
- FCN 02-20-2025
- Dividend Yield
- IONS N/A
- FCN N/A
- EPS Growth
- IONS N/A
- FCN 1.30
- EPS
- IONS N/A
- FCN 7.81
- Revenue
- IONS $705,000,000.00
- FCN $3,698,652,000.00
- Revenue This Year
- IONS N/A
- FCN $7.62
- Revenue Next Year
- IONS $10.08
- FCN $4.98
- P/E Ratio
- IONS N/A
- FCN $21.01
- Revenue Growth
- IONS N/A
- FCN 6.00
- 52 Week Low
- IONS $30.23
- FCN $161.24
- 52 Week High
- IONS $52.34
- FCN $243.60
- Technical
- Relative Strength Index (RSI)
- IONS 48.36
- FCN 22.61
- Support Level
- IONS $30.86
- FCN $186.82
- Resistance Level
- IONS $34.74
- FCN $190.69
- Average True Range (ATR)
- IONS 1.35
- FCN 4.98
- MACD
- IONS 0.18
- FCN -2.95
- Stochastic Oscillator
- IONS 46.34
- FCN 10.29
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
About FCN FTI Consulting Inc.
FTI Consulting Inc is a firm that generates its sales by providing professional business advisory services to customers. The company operates through five segments, namely corporate finance and restructuring, forensic and litigation consulting, economic consulting, technology, and strategic communications. The company generates the majority of its revenue from the Corporate finance segment. Customers of the company come from a wide array of sectors, including construction, energy and power, environmental, financial institutions, healthcare and life science, insurance, real estate and infrastructure, retail and consumer products, telecom, media, and technology. The majority of the company's revenue is derived from serving customers in the United States.